Here is a quick update on the ever-evolving world of COVID-19 trials. Since our initial posting on this topic, three weeks ago, the number of trials has grown from 100 to over 300. The number of clinical facilities with clinical trials for COVID-19 has grown from 160 to over 600. The fairly optimistic results about Gilead’s remdesivir, at the beginning of May, was a small sign of hope for patients and their families. You can seek entrance to these ongoing trials in over 140 facilities in the US and 70 in the EU (list of over 200 clinical facilities in the [...]
About ozmosi_adminThis author has not yet filled in any details.
So far ozmosi_admin has created 25 blog entries.
We all know the basics for fighting the COVID-19 virus, like washing our hands and staying socially distant from one another, but what about future vaccines and treatments? There is a lot of talk right now about different companies making progress and potential treatments on their way, but what is available right now? Where can patients go today to get the treatment they need? Below we describe the current treatments that are in the clinic right now and have listed for you all the facilities in the US and EU where patients can find a treatment in development for COVID-19. We [...]
When Good Things DON’T Come to Those Who Wait: How Pharma Companies Compare in Governance Efficiencyozmosi_admin2019-07-31T15:54:00+00:00
Predicting when a competing product will be approved is essential in any commercial forecast and for any business insights team with their eye on the market. Here at OZMOSI, we have been spending our summer building out a machine learning approach to further improve our drug approval date forecasting. Typically, the industry uses a simple average of phase lengths by disease area. While we have employed a similar approach historically, with 400,000 clinical trials in our database (and counting) we feel we can do better. In our analysis to date, we have gained some interesting perspective on the elements that go [...]
Keeping up with pharmaceutical landscape around the world, especially in Asia, is essential in today’s market. Here are some of the biggest news stories emerging from Asian countries that are making big strides in drug development. China: Recently, China has been quickly advancing in the process of approving of new drugs. This is in accordance to the new drug registration procedure under the Chinese FDA(CFDA). This new process is helping China to beat other countries, including the US, in the process of bringing drugs to market. For example, China was able to grant Astrazeneca and FribroGen approval for the drug [...]
Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China. Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world. China’s current trial pipeline below illustrates a disease area focus that is on par with what we see and expect from the US, EU, and Japan. And that’s only the beginning. China is now taking a very active role in developing novel therapies directly, and not just for their own [...]
Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and universities in the same space. Looking back to the year 2000, 8 out of the top 10 clinical trial sponsors were large pharmaceutical companies. Historically, over the same time period, pharma companies accounted for more than 30% of all clinical trials. Today, not a single pharmaceutical company rises to the level of top 10 clinical trial sponsors, and they account [...]
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio of insulins continues to drive significant revenue with over $2.5 billion in Sales in 2016 alone. In the short acting market, Lilly’s Humalog® has competed primarily with Novo Nordisk’s NovoLog® with much of the battle between the two shifting from Sales Force to competing on PBM/payer access in recent years; physicians and patients do not see a whole lot of [...]
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®, which is expected to reach $1.2 billion in 2021.11 In the basal category, Novo Nordisk’s Levemir® has long been second to Sanofi’s Lantus, despite steadily increasing share over time. Hoping to break out in this category, in early 2016, Novo Nordisk launched Tresiba®, their next generation basal insulin to compete against Lantus® and Lantus’s successor Toujeo®. This [...]
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class. But Merck has no plans of stopping there with four different products in late stage development that appear to be promising. In conjunction with Pfizer, the company recently filed NDAs for three SGLT-2 inhibitors based on their ertugliflozin molecule – one as a monotherapy, another in combination with Januvia® (sitagliptin) and the third a combination with metformin. Despite expectations to launch with three [...]
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next market leader, and 2018 will be no exception. Diabetes is a very challenging market to compete in since there is intense pricing pressure as well as more recent pressures for stellar cardiovascular outcomes data. It is no longer sufficient to demonstrate superior efficacy compared to alternative treatments. Doctors and patients are looking for heightened safety profiles and [...]